Skip to main content
S&P 5007,619.98-0.48%DOW52,421.20-0.29%NASDAQ26,186.41-0.56%BTC$77,017.00-0.59%ETH$2,481.25-0.33%GOLD$4,332.90-0.44%OIL$101.77+0.37%
Smart Investors Daily
TR

NASDAQ · TRDA

Entrada Therapeutics, Inc.

Healthcare · Biotechnology

$7.05

Up+$0.25 (+3.68%)

Updated Sep 15, 2026, 1:11 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
413.53M
P/E ratio
-4.34
Dividend yield
0.00%
52-week range
$5.02 – $16.45
Volume
336.1K
Avg. volume
275.51K

Price performance

TRDA price history

1M range · 20 trading sessions · Daily adjusted prices

TRDA closed at $7.05 after 20 trading sessions, down 3.69% for the selected period.

Last close
$7.05
Period change
-3.69%
Period low
$6.42
Period high
$7.78
Daily close
View OHLC price history
TRDA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 14, 2026$6.80$7.07$6.72$7.05336.1K
Sep 11, 2026$6.49$6.81$6.29$6.80291.81K
Sep 10, 2026$7.00$7.175$6.38$6.42448.06K
Sep 9, 2026$7.47$7.55$7.02$7.11382.04K
Sep 8, 2026$7.02$7.70$6.945$7.52514.21K
Sep 4, 2026$7.11$7.17$7.00$7.13341.73K
Sep 3, 2026$7.31$7.4228$7.04$7.17395.56K
Sep 2, 2026$7.07$7.34$6.96$7.30306.54K
Sep 1, 2026$6.95$7.1785$6.80$7.07205.48K
Aug 31, 2026$6.84$7.17$6.76$7.05450.41K
Aug 28, 2026$7.18$7.24$6.935$7.00111.6K
Aug 27, 2026$7.02$7.37$6.80$7.27248.6K
Aug 26, 2026$7.55$7.64$6.9538$7.00229.32K
Aug 25, 2026$7.39$7.67$7.39$7.62269.98K
Aug 24, 2026$7.58$7.58$7.12$7.33184.25K
Aug 21, 2026$7.64$7.735$7.44$7.57141.02K
Aug 20, 2026$7.76$7.765$7.30$7.60250.04K
Aug 19, 2026$7.49$7.79$7.395$7.78241.84K
Aug 18, 2026$7.21$7.43$7.16$7.27129.76K
Aug 17, 2026$7.33$7.56$7.25$7.32193.11K

Latest TRDA news

The latest Smart Investors Daily articles mentioning TRDA.

Stock researchCompany · Overview

TRDA research

Overview

Company profile and research snapshot.

Company profile

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$13.00
Implied upside
—
Analysts
11
TRDA recent ratings
DateFirmRatingTarget
Jun 8, 2026GuggenheimBuy—
May 8, 2026HC Wainwright & Co.Neutral—
Apr 6, 2026OppenheimerOutperform—
Feb 18, 2026HC Wainwright & Co.Buy—
Feb 11, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company’s common stock to eight newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026. The options have an exercise price of $7.07 per share, which is equal to the closing price of the

Yahoo · Aug 5, 2026

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By